DASH and Blood Pressure: What the Meta-Analyses Report
Meta-analyses of randomised trials report that DASH reduced systolic blood pressure by 3.2 mmHg and diastolic by 2.5 (Filippou 2020) and by 6.74 and 3.54 mmHg (Saneei 2014), with larger reductions under energy restriction and in hypertensive subjects; a Cochrane review reports no clear differences in infarction, stroke or mortality against comparators, with low to very low certainty (Bensaaud 2025).
People with hypertension, kidney disease, or on BP/potassium-affecting medication should coordinate with a clinician
- Signs of disordered eating (food/weight preoccupation, restriction, bingeing, purging, compulsive exercise): see a qualified eating-disorder professional
- Diagnosed medical condition (diabetes, chronic kidney disease, heart failure, GI disease): see a registered dietitian or physician
- Pregnancy or breastfeeding: see a prenatal provider or registered dietitian
- Unintentional weight loss, difficulty swallowing, or persistent GI symptoms: seek medical evaluation
- Diagnosed hypertension or on BP/potassium-affecting medication: see a physician or dietitian
What the evidence says
The sources on this entry are meta-analyses of controlled trials of the DASH diet with blood pressure, lipids and inflammatory markers as outcomes, meta-analyses of cohort studies of DASH adherence and disease risk, and one Cochrane review of hard cardiovascular outcomes. Filippou 2020 (meta-analysis of 30 randomised trials, 5,545 participants) reports that DASH reduced systolic pressure by 3.2 mmHg and diastolic by 2.5 mmHg compared with control in adults with and without hypertension, with a stronger effect at sodium intakes above 2400 mg/d and ages under 50; Saneei 2014 (17 randomised trials, 2,561 participants) reports reductions of 6.74 mmHg systolic and 3.54 mmHg diastolic, greater with energy restriction and in hypertensive subjects. Chiavaroli 2019 (umbrella review) reports DASH associated with a 20% lower incidence of cardiovascular disease, 21% lower coronary heart disease, 19% lower stroke and 18% lower diabetes in cohorts, and blood-pressure reductions of 5.2 mmHg systolic and 2.60 mmHg diastolic in controlled trials. Sahebkar 2023 (meta-analysis of 17 controlled trials) reports reduced triglycerides and LDL cholesterol with no effect on total cholesterol or HDL; Soltani 2017 (meta-analysis of randomised trials) reports decreased serum hs-CRP (mean difference −1.01). In observational studies, DASH adherence was inversely associated with metabolic syndrome (Farhadnejad 2021, a systematic review of 8 observational studies and 4 clinical trials, which calls the interventional results somewhat controversial), with chronic kidney disease risk (Mozaffari 2020, meta-analysis of observational studies, pooled estimate 0.77) and with cancer mortality (Milajerdi 2018, meta-analysis of cohort studies, HR 0.85). Bensaaud 2025 (Cochrane review of 5 randomised trials, 1,397 participants) reports no clear differences in myocardial infarction, stroke or all-cause mortality between DASH and comparators, with certainty low to very low, and concludes that the effect of DASH on major cardiovascular outcomes remains inconclusive for lack of robust long-term evidence.
- 'DASH is only for people with high blood pressure.' The pattern benefits general cardiometabolic health too.
- 'You must eliminate all salt.' The aim is moderation, not zero sodium.
- 'DASH replaces blood-pressure medication.' It complements, not replaces, medical care.
- Do not claim any food, diet, or supplement cures, treats, or prevents any disease
- Do not diagnose nutrient deficiencies or medical conditions
- Do not promise specific weight-loss amounts or timelines
- Do not deliver individualized medical nutrition therapy or replace clinical care
- Agreement
- Direction recorded for 0 of 9 sources; not yet recorded for the rest.
- The claim's outcome
- Outcome not yet recorded
- Certainty
- No source states a certainty rating.
- Authors
- Sources share authors: L. Azadbakht (senior author of 2 sources).
- How the sources were read
- Some sources are based on abstracts, not full texts.
What each source measured and concluded (9)
- What it measured
- Systolic and diastolic blood pressure
- How it was read
- based on the abstract, not the full text
- What the review says it includes
- Systematic review and meta-analysis of randomized controlled trials
- Studies and participants, as stated
- 30 RCTs, n=5545 participants
- What it measured
- Systolic and diastolic blood pressure
- How it was read
- based on the abstract, not the full text
- What the review says it includes
- Systematic review and meta-analysis of RCTs
- Studies and participants, as stated
- N=2,561 across 17 RCTs (20 comparisons)
- What it measured
- Lipid profile (triglycerides, LDL, total cholesterol, HDL)
- How it was read
- based on the abstract, not the full text
- What the review says it includes
- Systematic review and meta-analysis of clinical controlled trials
- Studies and participants, as stated
- 17 studies, 2218 individuals
- What it measured
- Serum inflammatory marker (hs-CRP)
- How it was read
- based on the abstract, not the full text
- What the review says it includes
- Systematic review and meta-analysis of randomized trials
- Studies and participants, as stated
- 7 trials eligible; 6 studies with 451 participants in meta-analysis
- What it measured
- Incident cardiovascular disease (CVD) in prospective cohort studies; systolic blood pressure (SBP) in controlled trials.
- How it was read
- read in full text
- What the review says it includes
- Umbrella review of 7 systematic reviews and meta-analyses (3 of prospective cohort studies and 4 of controlled trials)
- Studies and participants, as stated
- N=942,140 participants across 15 studies (prospective cohort studies); N=4,414 participants across 31 studies (controlled trials)
- What it measured
- Cancer mortality by dietary quality indices
- How it was read
- based on the abstract, not the full text
- What the review says it includes
- Systematic review and meta-analysis of cohort studies
- Studies and participants, as stated
- 27 publications
- What it measured
- Risk of chronic kidney disease (CKD) by DASH diet adherence
- How it was read
- based on the abstract, not the full text
- What the review says it includes
- Systematic review and meta-analysis of observational studies
- Studies and participants, as stated
- 7 studies in review, 6 in meta-analysis; 568,213 participants including 16,694 CKD cases
- What it measured
- Risk of metabolic syndrome (incidence, prevalence, development)
- How it was read
- based on the abstract, not the full text
- What the review says it includes
- Systematic review (8 observational studies and 4 clinical trials)
- Studies and participants, as stated
- 12 eligible studies
- What it measured
- Myocardial infarction, heart failure, and stroke
- How it was read
- based on the abstract, not the full text
- What the review says it includes
- Systematic review of RCTs (Cochrane, GRADE)
- Studies and participants, as stated
- N=1397 participants across 5 RCTs (1075 in meta-analyses)
Every source below is shown with its study design and links to the original study. This is the audit trail.
“Abstract only” means the review read that paper’s abstract, not its full text; “screened only” means it was included at re-screening and not extracted. Both stay in the trail with their DOI, because how a source was read is part of the audit.